Spero Therapeutics (NASDAQ:SPRO – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. On average, analysts expect Spero Therapeutics to post ($0.97) EPS for the current fiscal year and ($0.93) EPS for the next fiscal year.
Spero Therapeutics Stock Down 5.6%
Shares of SPRO opened at $1.01 on Wednesday. The stock has a market capitalization of $58.82 million, a P/E ratio of 9.73 and a beta of 1.59. The firm has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $1.93. Spero Therapeutics has a twelve month low of $0.96 and a twelve month high of $3.08.
Insider Activity at Spero Therapeutics
In related news, insider Esther Rajavelu sold 40,851 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $1.04, for a total value of $42,485.04. Following the completion of the sale, the insider owned 946,000 shares of the company’s stock, valued at $983,840. This trade represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the stock. Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Cantor Fitzgerald assumed coverage on shares of Spero Therapeutics in a report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 target price for the company. Weiss Ratings cut Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Zacks Research raised Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Finally, HC Wainwright boosted their price target on Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Monday, September 14th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.
Check Out Our Latest Research Report on SPRO
About Spero Therapeutics
Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.
Read More
- Five stocks we like better than Spero Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
